These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 1414271)

  • 1. Tacrine in Alzheimer's disease.
    Eagger SA; Levy R; Sahakian BJ
    Acta Neurol Scand Suppl; 1992; 139():75-80. PubMed ID: 1414271
    [No Abstract]   [Full Text] [Related]  

  • 2. Assessment of the value of therapeutic monitoring of tacrine in Alzheimer's disease.
    Roberts CJ; Ford JM; Truman CA; Scott M; Mäkelä PM; Wilcock GK
    Eur J Clin Pharmacol; 1998; 54(9-10):721-4. PubMed ID: 9923574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A double-blind crossover pilot study of l-deprenyl (selegiline) combined with cholinesterase inhibitor in Alzheimer's disease.
    Schneider LS; Olin JT; Pawluczyk S
    Am J Psychiatry; 1993 Feb; 150(2):321-3. PubMed ID: 8422085
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An enriched-population, double-blind, placebo-controlled, crossover study of tacrine and lecithin in Alzheimer's disease. The Tacrine 970-6 Study Group.
    Foster NL; Petersen RC; Gracon SI; Lewis K
    Dementia; 1996; 7(5):260-6. PubMed ID: 8872417
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of tacrine hydrochloride (Cognex) in two parallel-group studies.
    Gracon SI
    Acta Neurol Scand Suppl; 1996; 165():114-22. PubMed ID: 8740998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Guidelines for the use of tacrine in Alzheimer's disease: clinical application and effectiveness. Johns Hopkins Dementia Research Clinic.
    Lyketsos CG; Corazzini K; Steele CD; Kraus MF
    J Neuropsychiatry Clin Neurosci; 1996; 8(1):67-73. PubMed ID: 8845704
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment outcome of tacrine therapy depends on apolipoprotein genotype and gender of the subjects with Alzheimer's disease.
    Farlow MR; Lahiri DK; Poirier J; Davignon J; Schneider L; Hui SL
    Neurology; 1998 Mar; 50(3):669-77. PubMed ID: 9521254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tacrine in Alzheimer's disease.
    Davies B; Andrewes D; Stargatt R; Ames D; Tuckwell V; Davis S
    Lancet; 1989 Jul; 2(8655):163-4. PubMed ID: 2567933
    [No Abstract]   [Full Text] [Related]  

  • 9. A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group.
    Davis KL; Thal LJ; Gamzu ER; Davis CS; Woolson RF; Gracon SI; Drachman DA; Schneider LS; Whitehouse PJ; Hoover TM
    N Engl J Med; 1992 Oct; 327(18):1253-9. PubMed ID: 1406817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential neuropsychiatric symptom responses to tacrine in Alzheimer's disease: relationship to dementia severity.
    Kaufer D; Cummings JL; Christine D
    J Neuropsychiatry Clin Neurosci; 1998; 10(1):55-63. PubMed ID: 9547467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tacrine (tetrahydroaminoacridine; THA) and lecithin in senile dementia of the Alzheimer type: a multicentre trial. Groupe Français d'Etude de la Tetrahydroaminoacridine.
    Chatellier G; Lacomblez L
    BMJ; 1990 Feb; 300(6723):495-9. PubMed ID: 2107926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Delayed matching-to-sample performance during a double-blind trial of tacrine (THA) and lecithin in patients with Alzheimer's disease.
    Perryman KM; Fitten LJ
    Life Sci; 1993; 53(6):479-86. PubMed ID: 8341134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of tacrine and lecithin in mild to moderate Alzheimer's disease: double blind trial.
    Maltby N; Broe GA; Creasey H; Jorm AF; Christensen H; Brooks WS
    BMJ; 1994 Apr; 308(6933):879-83. PubMed ID: 8173365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Key methodological features of randomized controlled trials of Alzheimer's disease therapy. Minimal clinically important difference, sample size and trial duration.
    Burback D; Molnar FJ; St John P; Man-Son-Hing M
    Dement Geriatr Cogn Disord; 1999; 10(6):534-40. PubMed ID: 10559571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tacrine in Alzheimer's disease. Time course of changes in cognitive function and practice effects.
    Eagger S; Morant N; Levy R; Sahakian B
    Br J Psychiatry; 1992 Jan; 160():36-40. PubMed ID: 1544011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tacrine in Alzheimer's disease.
    Eagger SA; Levy R; Sahakian BJ
    Lancet; 1991 Apr; 337(8748):989-92. PubMed ID: 1673209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tacrine in Alzheimer's disease.
    Lancet; 1991 Jun; 337(8755):1475-6. PubMed ID: 1675337
    [No Abstract]   [Full Text] [Related]  

  • 18. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. The Tacrine Study Group.
    Knapp MJ; Knopman DS; Solomon PR; Pendlebury WW; Davis CS; Gracon SI
    JAMA; 1994 Apr; 271(13):985-91. PubMed ID: 8139083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Tacrine in the treatment of Alzheimer's disease].
    Weinstein HC; Teunisse S; van Gool WA; van Crevel H
    Ned Tijdschr Geneeskd; 1991 Aug; 135(35):1575-7. PubMed ID: 1922487
    [No Abstract]   [Full Text] [Related]  

  • 20. Long-term tacrine treatment effects.
    Knopman D; Schneider L; Davis K; Gracon S; Smith F
    Neurology; 1998 Feb; 50(2):567-8. PubMed ID: 9484404
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.